IJR News — today's news from every side
+6 Tom Gallagher Lilly is betting big on InnoCare's platform with those billions in milestones, but execution will decide if it pays off.+7 Sam Okafor Hope this Onswik stays affordable so more type 2 patients can actually use it.+7 Maya Lindstrom Hope this oral GLP-1 pill becomes more affordable once production ramps up locally.
+13 Marcus Bell Rebranding to just Novo feels like a distraction when their obesity share has already slipped to 38 percent against Lilly.+2 Tom Gallagher Curious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.
BMS to Build $2.3B Houston Campus; Lilly Expands x/united-states-of-america — Aug 10, 2026 Bristol Myers Squibb is investing about $2.3 billion to build a 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, part of its $40 billion five-year U.S. investment plan, to produce small molecules, biologics, and antibody-drug conjugates while enabling future expansion. The project will create roughly 500 permanent jobs and about 2,000 construction roles through 2030, supported by Texas incentives, as drugmakers continue expanding domestic manufacturing under government pressure to boost U.S. production. +29 Insurers, Medical Stocks Rally Ahead of Earnings Business — Jul 20, 2026 From penny-stock hopefuls like Vizsla Silver and Clover Health to heavyweight medical names such as Danaher, Intuitive Surgical and Eli Lilly, investors are weighing high-growth potential against execution risk as volumes, profitability, and catalysts drive attention. Insurance stocks Cincinnati Financial, Reinsurance Group of America, Oscar Health, Willis Towers Watson and Aflac are poised to outperform, while Custom Health Holdings’ bid for Evergreen Pharmacy and Alnylam Pharmaceuticals’ RNAi-focused pipeline illustrate ongoing deal activity and biotech risk-reward in a rate-sensitive, geopolitically unsettled market. +12
